AI assistant
Sending…
ELI LILLY & Co — Director's Dealing 2021
Feb 11, 2021
29745_dirs_2021-02-10_49447975-0e97-4579-b7c3-a21e543b513a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2021-02-08
Reporting Person: White Anne E. (SVP & Pres-Lilly Oncology)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-08 | Common Stock | A | 4718 | $205.77 | Acquired | 33840 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-08 | Restricted Stock Unit | $ | A | 9368 | Acquired | 2022-02-01 | Common Stock (9368.0) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
More from ELI LILLY & Co
Regulatory Filings
2026
May 11
Prospectus
2026
May 8
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 6
Prospectus
2026
May 6
Major Shareholding Notification
2026
May 1
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 29
Major Shareholding Notification
2026
Apr 20